Reddy J K, Azarnoff D L, Svoboda D J, Prasad J D
J Cell Biol. 1974 May;61(2):344-58. doi: 10.1083/jcb.61.2.344.
Nafenopin (2-methyl-2[p-(1,2,3,4-tetrahydro-1-naphthyl)phenoxy]-propionic acid; Su-13437), a potent hypolipidemic compound, was administered in varying concentrations in ground Purina Chow to male and female rats, wild type (Cs(a) strain) mice and acatalasemic (Cs(b) strain) mice to determine the hepatic microbody proliferative and catalase-inducing effects. In all groups of animals, administration of nafenopin at dietary levels of 0.125% and 0.25% produced a significant and sustained increase in the number of peroxisomes. The hepatic microbody proliferation in both male and female rats and wild type Cs(a) strain mice treated with nafenopin was of the same magnitude and was associated with a two-fold increase in catalase activity and in the concentration of catalase protein. The increase in microbody population in acatalasemic mice, although not accompanied by increase in catalase activity, was associated with a twofold increase in the amount of catalase protein. The absence of sex difference in microbody proliferative response in nafenopin-treated rats and wild type mice is of particular significance, since ethyl-alpha-p-chlorophenoxyisobutyrate (CPIB)-induced microbody proliferation and increase in catalase activity occurred only in males. Nafenopin can, therefore, be used as an inducer of microbody proliferation and of catalase synthesis in both sexes of rats and mice. The serum glycerol-glycerides were markedly lowered in all the animals given nafenopin, which paralleled the increase in liver catalase. All the above effects of nafenopin were fully reversed when the drug was withdrawn from the diet of male rats. During reversal, several microbody nucleoids were seen free in the hyaloplasm or in the dilated endoplasmic reticulum channels resulting from a rapid reduction in microbody matrix proteins after the withdrawal of nafenopin from the diet. Because of microbody proliferation and catalase induction with increasing number of hypolipidemic compounds, additional studies are necessary to determine the interrelationships of microbody proliferation, catalase induction, and hypolipidemia.
萘苯丁酸(2-甲基-2-[对-(1,2,3,4-四氢-1-萘基)苯氧基]-丙酸;Su-13437)是一种强效降血脂化合物,将其以不同浓度混入普瑞纳牌饲料中,喂给雄性和雌性大鼠、野生型(Cs(a)品系)小鼠以及无过氧化氢酶血症小鼠(Cs(b)品系),以确定其对肝脏微体增殖和过氧化氢酶诱导的作用。在所有动物组中,以0.125%和0.25%的膳食水平给予萘苯丁酸,可使过氧化物酶体数量显著且持续增加。用萘苯丁酸处理的雄性和雌性大鼠以及野生型Cs(a)品系小鼠的肝脏微体增殖程度相同,且过氧化氢酶活性和过氧化氢酶蛋白浓度增加了两倍。无过氧化氢酶血症小鼠微体数量的增加,虽然未伴随过氧化氢酶活性增加,但与过氧化氢酶蛋白量增加两倍有关。在用萘苯丁酸处理的大鼠和野生型小鼠中,微体增殖反应不存在性别差异,这一点尤为重要,因为α-对氯苯氧异丁酸乙酯(CPIB)诱导的微体增殖和过氧化氢酶活性增加仅发生在雄性动物中。因此,萘苯丁酸可作为大鼠和小鼠两性微体增殖和过氧化氢酶合成的诱导剂。给予萘苯丁酸的所有动物血清甘油三酯均显著降低,这与肝脏过氧化氢酶的增加平行。当从雄性大鼠的饮食中撤去该药物时,萘苯丁酸的所有上述作用均完全逆转。在逆转过程中,由于从饮食中撤去萘苯丁酸后微体基质蛋白迅速减少,可见一些微体核仁游离于透明质或扩张的内质网通道中。由于越来越多的降血脂化合物会导致微体增殖和过氧化氢酶诱导,因此需要进行更多研究以确定微体增殖、过氧化氢酶诱导和降血脂之间的相互关系。